BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25742485)

  • 21. Non-metastatic stage IV nasopharyngeal carcinoma patients: analysis of the pattern of relapse and survival.
    Ozyar E; Gurkaynak M; Yildiz F; Atahan IL
    Radiother Oncol; 2004 Jul; 72(1):71-7. PubMed ID: 15236877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
    Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
    Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Value of Cervical Nodal Necrosis in Nasopharyngeal Carcinoma: Analysis of 1800 Patients with Positive Cervical Nodal Metastasis at MR Imaging.
    Lan M; Huang Y; Chen CY; Han F; Wu SX; Tian L; Zheng L; Lu TX
    Radiology; 2015 Aug; 276(2):536-44. PubMed ID: 25759968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of MRI-derived masticator space involvement in IMRT-treated nasopharyngeal carcinoma patients.
    Xiao Y; Pan J; Chen Y; Lin S; Chen Y; Zong J; Fang Y; Guo Q; Chen B; Tang L
    Radiat Oncol; 2015 Sep; 10():204. PubMed ID: 26407897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients with cervical nodal necrosis.
    Lan M; Chen C; Huang Y; Tian L; Duan Z; Han F; Liao J; Deng M; Sio TT; Prayongrat A; Zheng L; Wu S; Lu T
    Sci Rep; 2017 Feb; 7():42624. PubMed ID: 28211482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pretreatment anemia and survival in nasopharyngeal carcinoma.
    Zhang LN; Tang J; Lan XW; OuYang PY; Xie FY
    Tumour Biol; 2016 Feb; 37(2):2225-31. PubMed ID: 26358251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognostic value of pretreatment tumor apparent diffusion coefficient values in nasopharyngeal carcinoma.
    Yan DF; Zhang WB; Ke SB; Zhao F; Yan SX; Wang QD; Teng LS
    BMC Cancer; 2017 Oct; 17(1):678. PubMed ID: 29020937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The value of the Prognostic Nutritional Index (PNI) in predicting outcomes and guiding the treatment strategy of nasopharyngeal carcinoma (NPC) patients receiving intensity-modulated radiotherapy (IMRT) with or without chemotherapy.
    Miao J; Xiao W; Wang L; Han F; Wu H; Deng X; Guo X; Zhao C
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1263-1273. PubMed ID: 28247035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evaluation of induction chemotherapy with vinorelbine plus cisplatin (NP) or docetaxel plus cisplatin (TP) combined with concurrent chemoradiotherapy for patients with locally advanced nasopharyngeal carcinoma].
    Han SH; Yu L; Zhang Z; Zhang PJ; Song HP; Guo CY
    Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):623-6. PubMed ID: 24314223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Posterior cervical lymph node metastasis as the valuable prognostic factor for stage IVA/IVB nasopharyngeal carcinoma treated with induction chemotherapy followed by concurrent chemo-radiotherapy.
    Thephamongkhol K; Setakornnukul J; Rojwatkarnjana S; Chansilpa Y
    Int J Biol Markers; 2014 Dec; 29(4):e387-94. PubMed ID: 25198554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial.
    Chen QY; Wen YF; Guo L; Liu H; Huang PY; Mo HY; Li NW; Xiang YQ; Luo DH; Qiu F; Sun R; Deng MQ; Chen MY; Hua YJ; Guo X; Cao KJ; Hong MH; Qian CN; Mai HQ
    J Natl Cancer Inst; 2011 Dec; 103(23):1761-70. PubMed ID: 22056739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers.
    Yang XL; Wang Y; Liang SB; He SS; Chen DM; Chen HY; Lu LX; Chen Y
    BMC Cancer; 2018 May; 18(1):606. PubMed ID: 29843648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities.
    Sun X; Su S; Chen C; Han F; Zhao C; Xiao W; Deng X; Huang S; Lin C; Lu T
    Radiother Oncol; 2014 Mar; 110(3):398-403. PubMed ID: 24231245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Value of Circulating Lipoprotein in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
    Yao JJ; He XJ; Lawrence WR; Zhang WJ; Kou J; Zhang F; Zhou GQ; Wang SY; Sun Y
    Cell Physiol Biochem; 2018; 48(1):285-292. PubMed ID: 30011397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Tumour Response to Induction Chemotherapy has Prognostic Value for Long-Term Survival Outcomes after Intensity-Modulated Radiation Therapy in Nasopharyngeal Carcinoma.
    Peng H; Chen L; Zhang Y; Li WF; Mao YP; Liu X; Zhang F; Guo R; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
    Sci Rep; 2016 Apr; 6():24835. PubMed ID: 27099096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implication of comorbidity on the initiation of chemotherapy and survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma.
    Guo R; Mao YP; Chen L; Tang LL; Zhou GQ; Liu LZ; Tian L; Zeng MS; Jia WH; Shao JY; Lin AH; Ma J
    Oncotarget; 2017 Feb; 8(6):10594-10601. PubMed ID: 27070084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The elevated pretreatment platelet-to-lymphocyte ratio predicts poor outcome in nasopharyngeal carcinoma patients.
    Jiang R; Zou X; Hu W; Fan YY; Yan Y; Zhang MX; You R; Sun R; Luo DH; Chen QY; Huang PY; Hua YJ; Guo L; Chen MY
    Tumour Biol; 2015 Sep; 36(10):7775-87. PubMed ID: 25944165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction Chemotherapy plus Concurrent Chemoradiotherapy vs Concurrent Chemoradiotherapy in Elderly Patients with Advanced Nasopharyngeal Carcinoma.
    Wang C; Tang X; Wang J; Song J; Xu Y
    Otolaryngol Head Neck Surg; 2017 Aug; 157(2):233-238. PubMed ID: 28418781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-Term Results of Concurrent Chemoradiotherapy for Advanced N2-3 Stage Nasopharyngeal Carcinoma.
    Yin L; Bian XH; Wang X; Chen M; Wu J; Xu JH; Qian PD; Guo WJ; Jiang XS; Zhu HF; Gu JJ; Wu JF; Zhang YW; He X
    PLoS One; 2015; 10(9):e0137383. PubMed ID: 26367317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metastatic nasopharyngeal carcinoma: Patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy.
    Rusthoven CG; Lanning RM; Jones BL; Amini A; Koshy M; Sher DJ; Bowles DW; McDermott JD; Jimeno A; Karam SD
    Radiother Oncol; 2017 Jul; 124(1):139-146. PubMed ID: 28433411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.